[Edaily Reporter Lee Hye-ra] #Chaperone announced on the 12th via a regulatory filing that it has decided to acquire a stake in Neztech, a company specializing in beauty devices.
Through this acquisition, Chaperone will secure management control of NezTech and become its largest shareholder. It has also secured a right of first refusal on the remaining shares to maintain cooperation with the existing management team and maximize synergies between the two companies.
This equity acquisition is intended to add a stable revenue base to Chaperone’s business structure, which is centered on new drug development, and to enhance corporate value by combining Chaperone’s biotechnology with NezTech’s expertise in the beauty device business. Through NezTech, Chaperone will secure a business portfolio capable of generating short-term revenue while strengthening its investment capacity to advance R&D for its core new drug pipeline and pursue global technology transfers.
NezTech is a specialized beauty device company that operates the home healthcare brand “Hugrap” and the beauty brand “Beaud.” It secures profitability through a direct sales structure centered on its own online store. NezTech has established an efficient business structure based on domestic and international OEM and ODM partnerships without maintaining its own production facilities. As of last year, sales through its own online store accounted for 77.7% of total revenue. The company has no accumulated losses and maintains virtually debt-free operations. It recorded an average annual growth rate exceeding 80% from 2023 to 2025. It is now actively expanding into the North American and Greater China markets.
Chaperone plans to utilize its U.S. subsidiary, Hudson Therapeutics, as a hub for its North American operations. Leveraging Hudson’s local network, the company aims to support the entry of NezTech’s products into the U.S. market and expects to generate revenue in North America as early as the second half of this year.
Chaperone is currently developing an innovative drug pipeline that includes “NuGel,” a next-generation atopic dermatitis treatment currently in a U.S. FDA Phase 2b clinical trial, as well as the Alzheimer’s treatment “NuCerin” and the immuno-oncology drug “Papiliximab.” In particular, the GPCR19-based inflammation control technology and anti-inflammatory/anti-aging ingredient technology secured during the development of NuGel are evaluated as valuable assets with high potential for expansion into the functional cosmetics and beauty device sectors.
Chaperone plans to begin developing new beauty products utilizing this raw material technology and, by combining it with NezTech’s product planning and sales capabilities, introduce differentiated functional beauty products.
Through this acquisition, Chaperone has secured a business foundation that allows it to generate stable cash flow while maintaining the growth potential of a biopharmaceutical company. The company plans to alleviate market concerns regarding earnings volatility and financial risk by leveraging the revenue and profits generated by NezTech, and to expand investments in R&D for its core pipeline and global technology transfer operations.
A Chaperone spokesperson stated, “We will create a new growth model for biotech companies by expanding investment in core pipeline R&D and global technology transfer based on stable cash flow,” adding, “We will continue to strengthen our business portfolio and consistently increase our corporate value through strategic M&A.”